Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)

NCT01873157 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT01873157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01873157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
February 28, 2017
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibody-mediated rejection, late rejection of renal transplant